Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Caffeine and myocardial perfusion: a clinical perspective

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • John Kurhanewicz
  • Daniel B Vigneron
  • Jan Henrik Ardenkjaer-Larsen
  • James A Bankson
  • Kevin Brindle
  • Charles H Cunningham
  • Ferdia A Gallagher
  • Kayvan R Keshari
  • Andreas Kjaer
  • Christoffer Laustsen
  • David A Mankoff
  • Matthew E Merritt
  • Sarah J Nelson
  • John M Pauly
  • Philips Lee
  • Sabrina Ronen
  • Damian J Tyler
  • Sunder S Rajan
  • Daniel M Spielman
  • Lawrence Wald
  • Xiaoliang Zhang
  • Craig R Malloy
  • Rahim Rizi
Vis graf over relationer

This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

OriginalsprogEngelsk
TidsskriftNeoplasia (New York, N.Y.)
Vol/bind21
Udgave nummer1
Sider (fra-til)1-16
Antal sider16
ISSN1522-8002
DOI
StatusUdgivet - jan. 2019

ID: 56695101